Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy
Citation
Allen , W L , Dunne , P D , McDade , S , Scanlon , E , Loughrey , M , Coleman , H , McCann , C , McLaughlin , K , Nemeth , Z , Syed , N , Jithesh , P , Arthur , K , Wilson , R , Coyle , V , McArt , D , Murray , G , Samuel , L , Nuciforo , P , Jimenez , J , Argiles , G , Dienstmann , R , Tabernero , J , Picariello , L , Messerini , L , Nobili , S , Mini , E , Sheahan , K , Ryan , E , Johnston , P G , Van Schaeybroeck , S , Lawler , M & Longley , D B 2018 , ' Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy ' , JCO Precision Oncology , vol. 2018 , no. 2 , pp. 1-15 . https://doi.org/10.1200/PO.17.00241
Rights
© 2018 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/